Recent Quarterly Results
STAAR Surgical Reports Second Quarter 2025 Results
- Net sales of $44.3 million down 55% Y/Y due to planned reduction of channel inventory in China
- Net sales excluding China of $39.0 million up 10% Y/Y
- Gross margin at 74.0% vs. 79.2% year ago due to the decrease in sales volume, but up from 65.8% in Q1 of this year
- Net loss of $(16.8) million or $(0.34) per share, down from net income of $7.4 million or $0.15 per share year ago, but up from a net loss of $(54.2) million or $(1.10) per share in Q1 2025
- Adjusted EBITDA1 loss of $(14.9) million or $(0.30) per share, down from Adjusted EBITDA income of $22.5 million or $0.45 per share year ago, but up from an Adjusted EBITDA loss of $(26.4) million or $(0.53) per share in Q1 2025
STAAR Surgical Reports First Quarter 2025 Results
- Net sales of $42.6 million down 45% Y/Y due to planned reduction of channel inventory in China
- Net Sales Excluding China of $42.2 million up 9% Y/Y reflecting growth in all key markets
- Gross margin at 65.8% vs. 78.9% year ago due to intentional reduction in U.S. production volumes and readiness for manufacturing in Switzerland
- Net loss of $(54.2) million or $(1.10) per share vs. $(3.3) million or $(0.07) per share year ago
- Adjusted EBITDA1 loss of $(26.4) million or $(0.53) per share vs. earnings of $5.3 million or $0.11 per share year ago
STAAR Surgical Reports Fourth Quarter and Fiscal Year 2024 Results
- Net Sales of $313.9 Million and ICL Sales of $312.5 Million for Fiscal 2024 Impacted by Weak China Macroeconomic Conditions
- ICL Sales Ex. China Up 17% in Fourth Quarter and 13% in Fiscal 2024
- Introduces Outlook for Fiscal 2025
- Earnings Conference Call and Webcast Today at 5:00 p.m. Eastern
STAAR Surgical Reports Third Quarter 2024 Results
- Net Sales Up 10% to $88.6 Million Driven by Growth in All Regions
- Americas Up 14%, EMEA Up 12% and APAC Up 9%
- Market Building Initiatives Drive EVO ICL™ Uptake and Reinforce Opportunity
STAAR Surgical Reports Second Quarter 2024 Results
- Record Quarterly Net Sales of $99.0 Million; $100.4 Million in Constant Currency
- Raises Fiscal 2024 Net Sales and Adjusted EBITDA Outlook
- ICL sales up 7% to $99.4 million and units up 3%
Annual Reports
Quarterly Results
